Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83116 | 0.95 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1190566 | 0.95 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1317731 | 0.88 | — | — | |
| SCHEMBL18586370 | 0.84 | — | — | |
| SCHEMBL14718566 | 0.82 | DPP4 (0.40) | NPC1RAB9A | |
| SCHEMBL10904550 | 0.81 | — | — | |
| SCHEMBL10904548 | 0.81 | — | — | |
| SCHEMBL80984 | 0.80 | TSHR (0.38) | — | |
| SCHEMBL29046163 | 0.80 | — | — | |
| SCHEMBL27650962 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230081426-A1 | COMPOUNDS AND METHODS FOR KRAS MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-03-16 | — | — | US | disclosed |
| US-8697685-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| EP-2362775-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| US-20060178359-A1 | Tricyclic compound, process for producing the same, and use | SYNGENTA CROP PROTECTION AG (CH) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275611-A1 | CHEMICAL COMPOUNDS | PDK1, PDK2, PDK3 | NPC1 2700/4885RAB9A 2582/4885SMN1; SMN2 4444/4885 |
| US-20230081426-A1 | COMPOUNDS AND METHODS FOR KRAS MODULATION AND INDICATIONS THEREFOR | KRAS, NRAS, HRAS | NPC1 1605/4885RAB9A 91/4885SMN1; SMN2 1298/4885 |
| US-20060178359-A1 | Tricyclic compound, process for producing the same, and use | CCR4, CCR5, CCR1 | NPC1 577/4885RAB9A 2938/4885SMN1; SMN2 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.